Free Trial
NASDAQ:ATRA

Atara Biotherapeutics (ATRA) Stock Price, News & Analysis

Atara Biotherapeutics logo
$12.24 +0.75 (+6.53%)
As of 03:27 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Atara Biotherapeutics Stock (NASDAQ:ATRA)

Key Stats

Today's Range
$11.62
$12.36
50-Day Range
$7.72
$13.02
52-Week Range
$5.01
$18.70
Volume
65,302 shs
Average Volume
111,445 shs
Market Capitalization
$85.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00
Consensus Rating
Moderate Buy

Company Overview

Atara Biotherapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
93rd Percentile Overall Score

ATRA MarketRank™: 

Atara Biotherapeutics scored higher than 93% of companies evaluated by MarketBeat, and ranked 84th out of 940 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Atara Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 2 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Atara Biotherapeutics has received no research coverage in the past 90 days.

  • Read more about Atara Biotherapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Atara Biotherapeutics are expected to grow in the coming year, from ($10.39) to ($10.04) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Atara Biotherapeutics is -28.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Atara Biotherapeutics is -28.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Percentage of Shares Shorted

    5.51% of the float of Atara Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Atara Biotherapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Atara Biotherapeutics has recently decreased by 21.42%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Atara Biotherapeutics does not currently pay a dividend.

  • Dividend Growth

    Atara Biotherapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    5.51% of the float of Atara Biotherapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Atara Biotherapeutics has a short interest ratio ("days to cover") of 3.6, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Atara Biotherapeutics has recently decreased by 21.42%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Atara Biotherapeutics has a news sentiment score of 1.49. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 13 news articles for Atara Biotherapeutics this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Atara Biotherapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $856,839.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 4.00% of the stock of Atara Biotherapeutics is held by insiders.

  • Percentage Held by Institutions

    70.90% of the stock of Atara Biotherapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Atara Biotherapeutics' insider trading history.
Receive ATRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Atara Biotherapeutics and its competitors with MarketBeat's FREE daily newsletter.

ATRA Stock News Headlines

Trump’s betrayal exposed
Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.tc pixel
Equities Analysts Issue Forecasts for ATRA Q1 Earnings
Atara Biotherapeutics: Q2 Earnings Snapshot
See More Headlines

ATRA Stock Analysis - Frequently Asked Questions

Atara Biotherapeutics' stock was trading at $13.31 at the beginning of 2025. Since then, ATRA shares have decreased by 9.6% and is now trading at $12.0290.

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) issued its quarterly earnings data on Monday, August, 11th. The biotechnology company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.51. The biotechnology company earned $17.58 million during the quarter, compared to analyst estimates of $4.23 million. Atara Biotherapeutics had a negative trailing twelve-month return on equity of 8.34% and a net margin of 3.07%.

Atara Biotherapeutics shares reverse split before market open on Thursday, June 20th 2024.The 1-25 reverse split was announced on Thursday, June 20th 2024. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, June 20th 2024. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

Top institutional shareholders of Atara Biotherapeutics include Geode Capital Management LLC (1.01%), Marshall Wace LLP (0.71%), Bank of America Corp DE (0.11%) and Raymond James Financial Inc. (0.06%). Insiders that own company stock include Innovation Ltd Panacea, Anhco Nguyen, Pascal Touchon, Eric J Hyllengren, Yanina Grant-Huerta, Jill Henrich, Carol Giltner Gallagher, Jakob Dupont, Amar Murugan, William K Heiden and Utpal Koppikar.
View institutional ownership trends
.

Shares of ATRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Atara Biotherapeutics investors own include Agenus (AGEN), CRISPR Therapeutics (CRSP), Pfizer (PFE), Athersys (ATHX), Advanced Micro Devices (AMD), Bristol Myers Squibb (BMY) and FuelCell Energy (FCEL).

Company Calendar

Last Earnings
8/11/2025
Today
8/22/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ATRA
CIK
1604464
Fax
N/A
Employees
330
Year Founded
2012

Price Target and Rating

High Price Target
$25.00
Low Price Target
$17.00
Potential Upside/Downside
+82.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.80
Research Coverage
5 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.43)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$85.40 million
Net Margins
3.07%
Pretax Margin
3.05%
Return on Equity
-8.34%
Return on Assets
6.61%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
1.70
Quick Ratio
1.70

Sales & Book Value

Annual Sales
$128.94 million
Price / Sales
0.63
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
($4.99) per share
Price / Book
-2.30

Miscellaneous

Outstanding Shares
7,020,000
Free Float
6,742,000
Market Cap
$80.66 million
Optionable
Optionable
Beta
0.26

Social Links

7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:ATRA) was last updated on 8/22/2025 by MarketBeat.com Staff
From Our Partners